Broader trials, which include but are not exclusive to individuals with FH, have demonstrated that PCSK9 inhibitors also lead to plaque volume reduction, as shown by intravascular ultrasonography in statin-treated CHD patients with stable disease [13] and acute myocardial infarction [14]. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.